<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The findings of morphologically dysplastic features in haemopoietic cells in de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) has been named <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS) </plain></SENT>
<SENT sid="1" pm="."><plain>We analysed the clinical data, karyotypes, and treatment outcomes of 230 de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients treated with the Japan Adult <z:mpath ids='MPATH_336'>Leukaemia</z:mpath> Study Group <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-87 protocol </plain></SENT>
<SENT sid="2" pm="."><plain>40 (17%) patients had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS </plain></SENT>
<SENT sid="3" pm="."><plain>Platelet count was significantly higher (P = 0.006) and bone marrow blasts were fewer (P = 0.01) in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS group than in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without TMDS </plain></SENT>
<SENT sid="4" pm="."><plain>Abnormal karyotype was shown in 12/30 patients (40%) analysed </plain></SENT>
<SENT sid="5" pm="."><plain>The complete remission (CR) rate for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS was significantly lower than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without TMDS (63% v 81%) (P = 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>The overall survival curves showed that the 40 patients with TMDS had a significantly worse survival than the 190 without TMDS (P = 0.0005) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS also showed significantly worse disease-free survival (DFS) (P = 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>Multivariate analysis revealed that the absence of TMDS in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was the most significant factor in obtaining CR (P = 0.01) and a significant factor in predicting longer DFS (P = 0.04) </plain></SENT>
<SENT sid="9" pm="."><plain>Our data suggest that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS responds poorly to intensive chemotherapy </plain></SENT>
<SENT sid="10" pm="."><plain>Further study is required to determine the best treatment strategy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS and the biological differences between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS and other types of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>